eIF4G (Ab-1231) Conjugated Antibody

Catalog No: #C21514



Package Size: #C21514-AF350 100ul #C21514-AF405 100ul #C21514-AF488 100ul

#C21514-AF555 100ul #C21514-AF594 100ul #C21514-AF647 100ul

#C21514-AF680 100ul #C21514-AF750 100ul #C21514-Biotin 100ul

Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Description

Product Name	elF4G (Ab-1231) Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of total eIF4G protein.
Immunogen Description	Peptide sequence around aa.1229~1233 (P-V-S-P-L) derived from Human elF4G.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Accession No.	Swiss-Prot#:Q04637NCBI Gene ID:1981NCBI mRNA#:NM_004953.3 NCBI Protein#:NP_004944.2
Uniprot	Q04637
GeneID	1981;
Excitation Emission	AF350: 346nm/442nm
	AF405: 401nm/421nm
	AF488: 493nm/519nm
	AF555: 555nm/565nm
	AF594: 591nm/614nm
	AF647: 651nm/667nm
	AF680: 679nm/702nm
	AF750: 749nm/775nm
Calculated MW	220
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250
AF405 conjugated: most applications: 1: 50 - 1: 250
AF488 conjugated: most applications: 1: 50 - 1: 250
AF555 conjugated: most applications: 1: 50 - 1: 250
AF594 conjugated: most applications: 1: 50 - 1: 250
AF647 conjugated: most applications: 1: 50 - 1: 250
AF680 conjugated: most applications: 1: 50 - 1: 250
AF750 conjugated: most applications: 1: 50 - 1: 250

 $Biotin \ conjugated: working \ with \ enzyme-conjugated \ streptavidin, \ most \ applications: \ 1:50 - 1:1,000$

Product Description

Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Background

eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis

Note: This product is for in vitro research use only